Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Optum Rx has introduced a host of tools at the formulary and benefit design levels, to ensure GLP-1 drugs are used responsibly
Understanding the root causes of obsessive-compulsive disorder and integrative strategies for support
What FDA Requires for NASH Approval FDA NASH Drug Approval Criteria (Based on Past Trials): Option 1: Histological Improvement (Biopsy-Based) NASH resolution (no inflammation, no ballooning) AND no worsening of fibrosis OR Fibrosis improvement (1 stage reduction) AND no worsening of NASH Option 2: Surrogate Endpoints (If Validated) Combination of imaging + biomarkers Must correlate with clinical outcomes Requires extensive validation Retatrutide's Current Status: Phase 2a: Fat reduction proven (surrogate endpoint) Phase 3 (TRIUMPH): Liver enzymes being measured (secondary) Still needs: Dedicated NASH trial with liver biopsies Phase 3 TRIUMPH: What Liver Data Will We Get
November 3, 2025: Ozempic Interferes With Medical Imaging Tests, Study Finds A study has found that taking Ozempic and other GLP-1 receptor agonists can cause issues with medical imaging tests (like PET scans)
